Does Recurrent Pancreatic Cancer Really Have Similar Outcome Compared With Primary Metastatic Pancreatic Cancer?
NCT ID: NCT06921252
Last Updated: 2025-04-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
276 participants
OBSERVATIONAL
2010-01-01
2025-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer
NCT06809374
Chemoradiotherapy With Gemcitabine/S-1 vs Gemcitabine/S-1 for Locally Advanced Pancreatic Cancer
NCT01430052
Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
NCT05268692
Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.
NCT04835064
An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer
NCT06129812
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
chemotherapy for metastatic pancreatic cancer
chemotherapy
chemotherapy agents
Overall, data of 276 patients (144 men and 132 women, 224 Rec-PC and 51 PM-PC) were retrospectively analyzed. The median patient age was 70 (range; 29-91) years. Serum carbohydrate antigen (CA) 19-9 among Rec-PC group (median; 207 U/mL) and PM-PC group (median; 1680 U/mL) was statistically different. Rec-PC patients received gemcitabine plus nab-paclitaxel (106), S-1 (37), gemcitabine (22), FOLRIFINOX (18) and other (8) regimen as a first line chemotherapy. 67 Rec-PC patients underwent any local treatment. PM-PC patients received gemcitabine plus nab-paclitaxel (34), FOLRIFINOX (8), gemcitabine (5), S-1 (2) and other (2) regimen as a first line chemotherapy.
chemotherapy for recurrent pancreatic cancer
postoperative chemotherapy
chemotherapy agents
Overall, data of 276 patients (144 men and 132 women, 224 Rec-PC and 51 PM-PC) were retrospectively analyzed. The median patient age was 70 (range; 29-91) years. Serum carbohydrate antigen (CA) 19-9 among Rec-PC group (median; 207 U/mL) and PM-PC group (median; 1680 U/mL) was statistically different. Rec-PC patients received gemcitabine plus nab-paclitaxel (106), S-1 (37), gemcitabine (22), FOLRIFINOX (18) and other (8) regimen as a first line chemotherapy. 67 Rec-PC patients underwent any local treatment. PM-PC patients received gemcitabine plus nab-paclitaxel (34), FOLRIFINOX (8), gemcitabine (5), S-1 (2) and other (2) regimen as a first line chemotherapy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
chemotherapy agents
Overall, data of 276 patients (144 men and 132 women, 224 Rec-PC and 51 PM-PC) were retrospectively analyzed. The median patient age was 70 (range; 29-91) years. Serum carbohydrate antigen (CA) 19-9 among Rec-PC group (median; 207 U/mL) and PM-PC group (median; 1680 U/mL) was statistically different. Rec-PC patients received gemcitabine plus nab-paclitaxel (106), S-1 (37), gemcitabine (22), FOLRIFINOX (18) and other (8) regimen as a first line chemotherapy. 67 Rec-PC patients underwent any local treatment. PM-PC patients received gemcitabine plus nab-paclitaxel (34), FOLRIFINOX (8), gemcitabine (5), S-1 (2) and other (2) regimen as a first line chemotherapy.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kochi University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Takehiro Okabayashi
Head of Surgery
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Kochi University
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.